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Objective. Antiphospholipid antibodies (aPL), es-
pecially those targetingb2-glycoprotein I (b2GPI), are well
known to activate endothelial cells, monocytes, and plate-
lets, with prothrombotic implications. In contrast, the
interaction of aPL with neutrophils has not been extensive-
ly studied. Neutrophil extracellular traps (NETs) have
recently been recognized as an important activator of the
coagulation cascade, as well as an integral component of
arterial and venous thrombi. This study was undertaken to
determine whether aPL activate neutrophils to release
NETs, thereby predisposing to the arterial and venous
thrombosis inherent in the antiphospholipid syndrome
(APS).
Methods. Neutrophils, sera, and plasma were pre-
pared from patients with primary APS (n5 52) or from
healthy volunteers and characterized. No patient had
concomitant systemic lupus erythematosus.
Results. Sera and plasma from patients with pri-
mary APS had elevated levels of both cell-free DNA and
NETs, as compared to healthy volunteers. Freshly isolated
neutrophils from patients with APS were predisposed to
high levels of spontaneous NET release. Further, APS
patient sera, as well as IgG purified from APS patients,
stimulated NET release from control neutrophils. Human
aPL monoclonal antibodies, especially those targeting
b2GPI, also enhanced NET release. The induction of APS
NETs was abrogated with inhibitors of reactive oxygen
species formation and Toll-like receptor 4 signaling.
Highlighting the potential clinical relevance of these find-
ings, APS NETs promoted thrombin generation.
Conclusion. Our findings indicate that NET
release warrants further investigation as a novel thera-
peutic target in APS.
Antiphospholipid syndrome (APS) is an autoim-
mune disease of unknown cause associated with elevated
titers of antiphospholipid antibodies (aPLs), which pre-
dispose to arterial and venous thrombosis, as well as fetal
loss (1). While first described in association with systemic
lupus erythematosus (SLE) (2), APS is now well recog-
nized to also exist as a primary autoimmune syndrome,
with thrombosis and pregnancy loss as its cardinal mani-
festations, and with other associated features including
thrombocytopenia, livedo reticularis, cognitive dysfunc-
tion, seizure disorder, and renal vasculopathy (1). Impor-
tantly, APS is relatively unique among prothrombotic
diatheses, in that it clearly predisposes to both arterial
and venous events. There is no cure for APS, and current
treatments focus on suppressing coagulation, rather than
targeting the underlying pathophysiology (3).
Clinically significant aPLs recognize both throm-
bin and b2-glycoprotein I (b2GPI), with antibodies to
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the latter having more uniform clinical testing and better
understood downstream signaling pathways (1). b2GPI, a
cationic lipid-binding protein produced by liver, endotheli-
al cells, monocytes, and trophoblasts, circulates at high lev-
els in plasma (50–200 mg/ml) (4,5). While some interesting
recent studies have suggested that b2GPI has specific and
important roles in innate immunity (6), the function of
this abundant plasma protein remains largely unknown.
It has been suggested that anti-b2GPI aPLs pro-
mote thrombosis by engaging the b2GPI protein on cell
surfaces and thereby activating cells, resulting in
increased tissue factor expression and release of proin-
flammatory cytokines such as tumor necrosis factor
(7–9). These processes have been extensively studied in
endothelial cells and monocytes, where annexin A2 and
Toll-like receptor 4 (TLR-4) function as important co-
receptors (7–9), and in platelets, where aPL/b2GPI
associate with and signal through apolipoprotein E
receptor 2 (10). Despite extensive study of the afore-
mentioned cell types, the interaction of aPLs with the
most abundant leukocyte in human blood, the neutro-
phil, has only rarely been considered (11–16). The limit-
ed studies that do exist suggest that aPLs can directly
activate neutrophils, as measured by enhanced granule
release, oxidative burst, and interleukin-18 production
(11,12), with possible amplification of this activation by
complement C5a (14,15).
With emerging recognition of links between neu-
trophils and thrombosis in nonautoimmune conditions
(17,18), there is now a compelling reason to further
explore aPL–neutrophil interplay. Neutrophil extracel-
lular trap (NET) release, a form of neutrophil cell death
that results in the externalization of decondensed chro-
matin decorated with granule and nuclear proteins (19),
has recently been recognized as an important mediator
of pathologic thrombosis. NETs form an integral part of
venous thrombi in animals and humans (17,20), with
NET-derived proteases activating the coagulation cas-
cade, and the NET structure serving as scaffolding for
clot assembly (21,22). Activated neutrophils and resul-
tant NETs are also known to damage the endothelium
(23,24) and have been recognized as potential mediators
of atherosclerosis and arterial thrombosis (25–27). We
therefore sought to determine whether NET release
might be a mechanism by which aPL–neutrophil inter-
play predisposes to thrombotic events in APS.
MATERIALS AND METHODS
Human subjects. Patients were recruited from Rheu-
matology and Hematology clinics at the University of Michigan
or from the Department of Immunology and Rheumatology at
the Instituto Nacional de Ciencias Medicas y Nutricion Salvador
Zubiran. All patients met the laboratory criteria for APS accord-
ing to the updated Sydney classification criteria (28). If patients
had only thrombocytopenia and/or hemolytic anemia (n5 6),
they were classified as having APS according to the classification
criteria of Alarcon-Segovia et al (29). All remaining patients with
primary APS (n5 46) met the full Sydney classification criteria.
Importantly, no APS patient in our primary cohort met the
American College of Rheumatology (ACR) criteria for SLE
(30); the only exceptions were the patients explicitly labeled as
having secondary APS in the serum-stimulation experiments.
This study was reviewed and approved by the Institutional
Review Boards from both institutions, and all patients gave their
written informed consent.
The Michigan population was predominantly Cauca-
sian (European American) and the Mexico population pre-
dominantly Hispanic (see Supplementary Table 1, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39247/abstract). Despite this dispari-
ty, we found no difference between the Michigan and Mexico
populations in any of the NET/neutrophil assays described in
this study (data not shown). Healthy volunteers were recruited
by advertisement at the University of Michigan; this control
population was predominantly Caucasian (see Supplementary
Table 1).
Blood was collected by phlebotomist venipuncture into
standard serum or 3.2% sodium citrate tubes. Serum and plas-
ma were prepared by standard methods and stored at 2808C
until ready for use. Levels of anti-b2GPI IgG, IgM, and IgA,
as well as anticardiolipin IgG and IgM, were determined with
commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Inova Diagnostics) according to the manufac-
turer’s instructions. Lupus anticoagulant (LAC) levels were
determined with a LAC/1 screening reactant and a confirma-
tory LAC/2 test according to published guidelines (31). Sup-
plementary Table 1 displays the demographic and clinical
characteristics of the patients included in the study.
Reagents. Human monoclonal aPLs were a generous
gift from Drs. Pojen Chen (David Geffen School of Medicine,
University of California, Los Angeles) and Barton Haynes (Duke
University School of Medicine, Durham, NC) and have been
described previously (32). Monoclonal antibodies and other puri-
fied reagents were determined to be free of endotoxin contamina-
tion via use of a chromogenic endotoxin quantification kit, used
according to the recommendations of the manufacturer (Pierce).
Other reagents are described within the individual assay proto-
cols below.
Quantification of cell-free DNA and myeloperoxidase
(MPO)–DNA complexes. Cell-free DNA was quantified in
serum and plasma using a Quant-iT PicoGreen double-stranded
DNA (dsDNA) assay kit (Invitrogen) according to the manufac-
turer’s instructions. MPO–DNA complexes were quantified sim-
ilarly to what has been previously described (33). This protocol
used several reagents from the Cell Death Detection ELISA kit
(Roche). First, a high-binding 96-well enzyme immunoassay/
radioimmunoassay (EIA/RIA) plate (Costar) was coated over-
night at 48C with anti-human MPO antibody (0400-0002; Bio-
Rad), diluted to a concentration of 5 mg/ml in coating buffer
(Cell Death kit). The plate was washed 3 times with wash buffer
(0.05% Tween 20 in phosphate buffered saline [PBS]), and then
blocked with 1% bovine serum albumin (BSA) in PBS for 90
minutes at room temperature. The plate was again washed 3
times before incubating overnight at 48C with 10% serum or
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plasma in the aforementioned blocking buffer. The plate was
washed 5 times, and then incubated for 90 minutes at room tem-
perature with 13 anti-DNA antibody (horseradish peroxidase
[HRP]–conjugated; Cell Death kit) diluted in blocking buffer.
After 5 more washes, the plate was developed with 3,30,5,50-tet-
ramethylbenzidine (TMB) substrate (Invitrogen) followed by a
2N sulfuric acid stop solution. Absorbance was measured at a
wavelength of 405 nm with a Synergy HT Multi-Mode Micro-
plate Reader (BioTek). Data were normalized to an in vitro–
prepared NET standard, which was included on every plate.
Cell isolation. Citrated blood from patients or healthy
volunteers was fractionated by density-gradient centrifugation
using Ficoll-Paque Plus (GE Healthcare) to separate peripheral
blood mononuclear cells (PBMCs) from neutrophils. Neutrophils
were then further purified by dextran sedimentation of the red
blood cell (RBC) layer, before lysing residual RBCs with 0.2%
sodium chloride. Neutrophil preparations were .98% pure as
confirmed by both flow cytometry and nuclear morphology.
Quantification of NETs by immunofluorescence. A
protocol similar to what has been described previously was fol-
lowed (34). Briefly, 1.5 3 105 neutrophils were seeded onto cov-
erslips coated with 0.001% poly-L-lysine (Sigma) and then
incubated in RPMI 1640 supplemented with L-glutamine. Experi-
ments were done in the absence of fetal bovine serum or human
serum unless explicitly stated otherwise. Neutrophils were stimu-
lated with a variety of reagents including phorbol myristate
acetate (PMA) (20 nM; Sigma), lipopolysaccharide (LPS) from
Escherichia coli (100 mg/ml; Sigma), and various human antibod-
ies at 10 mg/ml. Tested inhibitors included diphenyleneiodonium
(DPI) (20 mM; Tocris Bioscience), TLR-4 inhibitor TAK-242 (5–
10 mM; Millipore), anti–TLR-2 (clone T2.5) (10–25 mM; eBio-
science), anti–TLR-4 (HTA125) (10–25 mM; eBioscience), poly-
myxin B (50 mg/ml; Sigma), and anti-CD11b (clone M1/70) (10
mg/ml; BioLegend). Neutrophils were stimulated for 2–3 hours at
378C. For immunofluorescence-based quantification, cells were
fixed with 4% paraformaldehyde without permeabilization. DNA
was stained with Hoechst 33342 (Invitrogen). Protein staining was
performed with a rabbit polyclonal antibody to neutrophil elastase
(ab21595; Abcam) and fluorescein isothiocyanate–conjugated
anti-rabbit IgG (SouthernBiotech).
Images were obtained using an Olympus microscope
(IX70) and an HQ2 CoolSNAP monochrome camera (Photo-
metrics) with Metamorph Premier software. Image overlay
and background correction were performed with Metamorph,
and the recorded images were loaded into Adobe Photoshop
for further analysis. NETs (decondensed extracellular DNA
costaining with neutrophil elastase) were quantified by 2
observers under blinded conditions, with the results digitally
recorded to prevent multiple counts; the percentage of NETs
was calculated by averaging 5–10 403 fields per sample. To
quantify extracellular DNA, incubation was performed essen-
tially as above, but with 1 3 105 cells/well in 96-well tissue
culture black plates with clear bottoms (Costar). After incuba-
tion, 13 reagent from a Quant-iT PicoGreen dsDNA Assay
Kit was mixed 1:1 with the culture medium directly in the incu-
bation plate. After 5 minutes at room temperature, fluores-
cence was measured at an excitation wavelength of 480 nm
and an emission wavelength of 520 nm in a Synergy H1 Hybrid
Plate Reader (BioTek). When visualized by immunofluores-
cence microscopy, the only demonstrable staining after this
short incubation period was of extracellular DNA; no intact
nuclear DNA could be visualized. Representative images were
captured with an Olympus microscope (IX70) and a HQ2
CoolSNAP monochrome camera with Metamorph Premier
software.
Identification of low-density granulocytes (LDGs).
LDGs were identified and quantified by flow cytometry as previ-
ously described (35). Briefly, PBMCs were isolated from citrated
blood by density centrifugation (Ficoll-Paque Plus). Residual
RBCs were lysed with hypotonic saline, and cells were then
resuspended in flow buffer consisting of PBS supplemented
with 1% BSA and 1% horse serum. LDGs were identified by
their characteristic appearance on forward- and side-scatter
plots. LDGs were consistently CD10highCD14lowCD15high.
IgG purification. IgG was purified from APS or control
sera with a Protein G–Agarose kit according to the manufacturer’s
instructions (Pierce). Briefly, serum was diluted in IgG binding
buffer and passed through a protein G–agarose column at least
5 times. IgG was then eluted with 0.1M glycine and neutralized
with 1M Tris. This was followed by overnight dialysis against PBS
at 48C. IgG purity was verified with Coomassie staining, and con-
centrations were determined by bicinchoninic acid (BCA) protein
assay (Pierce) according to the manufacturer’s instructions.
F(ab0)2 generation. F(ab0)2 fragments were generated
and purified from total IgG fractions from healthy controls or
APS patients with a Pierce F(ab0)2 Preparation Kit, according
to the manufacturer’s instructions.
Anti-b2GPI depletion with purified b2GPI. High-
binding EIA/RIA plates were coated overnight at 48C with 10
mg/ml purified b2GPI (US Biologicals) diluted in coating buff-
er from a Cell Death Detection ELISA kit. Plates were then
washed with 0.05% Tween 20 in PBS, and blocked with 1%
BSA in PBS for 3 hours at room temperature. APS total IgG
fractions (10 mg/ml) were added to the plates and incubated
overnight at 48C with gentle shaking. As a negative control,
APS total IgG fractions were added to wells coated with BSA
(mock depletion). After overnight incubation, unbound APS
IgG was removed from the plates, sterile filtered, and used for
stimulation of neutrophils.
Western blotting. Cells were lysed by resuspending in
radioimmunoprecipitation assay buffer (50 mM Tris pH 7.4,
150 mM NaCl, 2 mM EDTA, 1% Triton X, and a Roche protease
inhibitor cocktail pellet) on ice for 1 hour. After spinning to
remove debris, protein concentration was measured with a BCA
Protein Assay Kit according to the manufacturer’s instructions.
Samples were resolved by 12% sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis under denaturing conditions, and trans-
ferred to a 0.45m nitrocellulose membrane. Primary antibodies
were directed against b2GPI (A80-142A), annexin A2 (ab178677;
Abcam), andb-actin (ab8227; Abcam). HRP-conjugated anti-goat
or anti-rabbit secondary antibodies (Jackson ImmunoResearch)
and Western Lightning Plus ECL (PerkinElmer) were used for
detection. Images were captured with an Omega Lum C detector,
and densitometry was performed using UltraQuant software
(Aplegen).
Immunofluorescence. Neutrophils (1.53 105) were
seeded onto coverslips coated with 0.001% poly-L-lysine and fixed
with 4% paraformaldehyde. In some experiments, cells were then
permeabilized with 0.1% Triton X for 15 minutes at room temper-
ature. Blocking was with 1% BSA. Antibodies to b2GPI and mye-
loperoxidase (A0398, Dako) were used as primary antibodies.
Appropriate fluorochrome-conjugated secondary antibodies were
from SouthernBiotech. DNA was stained with Hoechst 33342. An
Olympus microscope (IX70) was used for imaging.
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Flow cytometry. b2GPI expression on the cell surface
of control neutrophils and monocytes was determined by flow
cytometry, using a protocol similar to what has been described
previously (4). Freshly isolated control neutrophils and PBMCs
were stained with rabbit polyclonal anti-human b2GPI
(ABS162; Millipore), as well as anti-human CD10 (BioLegend)
as a neutrophil marker or anti-human CD14 (BioLegend) as a
monocyte marker. Staining was for 30 minutes at 48C. After
washing, cells were fixed in 2% paraformaldehyde before analy-
sis with a CyAn ADP Analyzer (Beckman Coulter). Further
data analysis was done in FlowJo.
Quantification of neutrophil H2O2 production. The
generation of H2O2 was quantified, essentially as described pre-
viously (36). Briefly, H2O2 production was detected by a colori-
metric assay, with 50 mM Amplex Red reagent (Invitrogen) and
10 units/ml HRP (Sigma) added to the culture medium. Absor-
bance was measured at 560 nm, and linearity was assured with
an H2O2 standard curve. The data were plotted with the no-
inhibitor PMA condition set to 100%, after subtracting for
background H2O2 production from unstimulated cells.
Thrombin generation assay. Thrombin generation was
measured as previously described (37). Platelet-poor plasma
(PPP) was prepared by centrifugation of citrated blood at 1,500g
for 10 minutes at room temperature. Control neutrophils (1 3
105) were added to 35-ml aliquots of PPP from healthy volunteers
or patients in wells of a 96-well black Costar plate. Where indi-
cated, PPP was treated with the following enzymes or antibodies
before the addition of neutrophils: DNase I (Pulmozyme [dor-
nase alfa]) (20 mg/ml; Genentech), HTF-1 (murine monoclonal
antibody against tissue factor) (10 mg/ml; BD Biosciences), or
APS IgG monoclonal antibodies (10 mg/ml). The sample volume
was brought to a final volume of 50 ml by the addition of PBS.
After incubation of neutrophils in plasma for 30 minutes
at 378C, coagulation was initiated by the addition of 50 ml of reac-
tion buffer containing 15 mM CaCl2 and 1 mM Z-Gly-Gly-Arg-
AMC (Bachem). Thrombin generation was then monitored using
a Technothrombin TGA thrombin generation assay (Techno-
clone). Thrombin generation profiles were analyzed using Tech-
nothrombin TGA software (Technoclone). Delta values were
calculated by subtracting the baseline condition (either plasma
alone or plasma supplemented with IgG) from the experimental
condition of interest (for example, plasma and neutrophils). Plas-
ma samples from patients treated with either warfarin or
heparin-based anticoagulants were not included in this analysis.
Statistical analysis. Unless otherwise indicated, results
are presented as the mean6 SEM. GraphPad Prism software
version 6 was used for data analysis. Data sets were tested for
Gaussian distribution by D’Agostino-Pearson omnibus normality
test. Pairs of data with a Gaussian distribution were analyzed by
unpaired t-test, while nonparametric data were assessed by
Figure 1. Elevated levels of cell-free DNA and neutrophil extracellular traps (NETs) in the circulation of patients with primary antiphospholipid
syndrome (APS). A, Levels of cell-free DNA in the plasma of patients with APS or healthy controls (n5 26 per group). B, Levels of circulating
NETs in the same plasma samples, measured by myeloperoxidase (MPO) DNA enzyme-linked immunosorbent assay (n5 21 controls and 26
patients with APS). C, Levels of cell-free DNA in serum samples from APS patients (n5 52) or healthy controls (n5 46). In A–C, symbols rep-
resent individual samples; horizontal and vertical lines show the mean6 SD. D, Correlation between cell-free DNA and circulating NETs
(MPO–DNA complexes) in APS sera (n5 52). *5P , 0.05; **5P , 0.01, versus control.
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Mann-Whitney test. Correlations were tested by Pearson’s corre-
lation coefficient. P values less than 0.05 were considered signifi-
cant, unless stated otherwise.
RESULTS
Given previous and extensive links between NETs
and both human and murine lupus (34,36,38–41), we
focused on patients with primary APS for the key experi-
ments of this study. All 52 patients with primary APS met
the Sydney laboratory criteria, while 46 fulfilled both the
Sydney criteria (28) and the criteria of Alarcon-Segovia
et al (29). Four patients had thrombocytopenia and 2 had
Evans’ syndrome as their sole clinical manifestation, and
therefore only fulfilled the clinical criteria of Alarcon-
Segovia et al (28,29). Importantly, none of the patients
with primary APS met the ACR criteria for SLE (30).
The 52 patients had an array of serologic positivity,
clinical manifestations, and medication usage, as shown
in Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract. No patient included in
this study had experienced a new thrombotic event in the
3 months prior to blood collection.
Increase in cell-free DNA and NETs in the cir-
culation of patients with APS. We first measured levels
of cell-free DNA and NETs in the plasma of APS patients
(n5 26). These levels are elevated in other disease process-
es with a prothrombotic diathesis, such as sepsis (37),
thrombotic microangiopathy (42), small vessel vasculitis
(33), and cancer (43). As compared to healthy controls, we
found plasma from patients with APS to have increased lev-
els of both cell-free DNA (Figure 1A) and NETs (Figure
1B), with the latter detected with an ELISA for MPO–
DNA complexes (33).
In general, serum samples contain more cell-free
DNA than plasma (44), which is probably the result of
the in vitro clot that forms during serum preparation.
Despite this potential background of nonspecific DNA,
others have had success measuring NETs in diseased
sera, for example in antineutrophil cytoplasmic antibody–
Figure 2. Enhanced neutrophil extracellular trap (NET) release in neutrophils from patients with primary antiphospholipid syndrome (APS).
A, NET release, determined by immunofluorescence microscopy, from freshly isolated neutrophils from healthy controls (n5 22) or APS patients
(n5 18) that were seeded onto coverslips and incubated in serum-free media for 2 hours. B, Representative immunofluorescence microscopy of
control and APS neutrophils. Blue indicates DNA; green indicates neutrophil elastase. Bars5 25m. C, NET release, determined by immunofluo-
rescence microscopy, from control neutrophils that were treated with 10% serum from heterologous healthy controls or APS patients for 2
hours. In A and C, symbols represent individual samples; horizontal and vertical lines show the mean6 SD (n5 27 controls, n5 35 patients with
APS, and n5 12 patients with secondary APS). *5P , 0.05; ***5P , 0.001; ****5P , 0.0001. NS5 not significant.
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associated vasculitis (33). Given our access to more serum
samples from APS patients (n5 52) than plasma, we also
tested the levels of cell-free DNA and NETs in these sam-
ples. Indeed, we found a significant increase in cell-free
DNA in APS sera as compared to control sera (Figure
1C). Further, cell-free DNA showed a statistically signifi-
cant correlation with circulating NETs in these samples
(Figure 1D), demonstrating that the cell-free DNA is at
least partially neutrophil derived. In summary, APS
patients have elevated levels of circulating cell-free DNA
and NETs as compared to healthy controls, even between
thrombotic episodes, suggesting that their neutrophils are
predisposed toward NET release.
Spontaneous release of NETs by neutrophils
from patients with primary APS. From a subset of the
APS patients, we isolated neutrophils for analysis of NET
release. Indeed, APS neutrophils demonstrated enhanced
spontaneous NET release as compared to controls (Figures
2A and B). Of note, these neutrophils were isolated by a
typical Ficoll protocol (see Materials and Methods) and
would therefore be considered of “normal” density. Spe-
cifically, they would not meet the criteria for the LDGs
that have been described at increased numbers in lupus
patients (35), and that are known to undergo exaggerated
NET release (34). To be as definitive as possible on this
point, we tested patients with primary APS for the pres-
ence of circulating LDGs. In contrast to lupus patients,
LDGs were only detected at low levels in patients with pri-
mary APS, similar to healthy controls (see Supplementary
Figure 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39247/abstract).
The assay of NET release described above (Figures
2A and B) was performed in the absence of specific in vitro
stimulation, suggesting that the primary stimulus for NET
release was provided in vivo before neutrophil isolation.
Indeed, there was a positive correlation between this in
vitro NET release and levels of circulating MPO–DNA
Figure 3. Effect of anti–b2-glycoprotein I (anti-b2GPI) IgG on the release of neutrophil extracellular traps (NETs) by neutrophils. A, NET
release, determined by immunofluorescence microscopy, from antiphospholipid syndrome (APS) IgG samples. Five APS IgG samples were
pooled, and then depleted of anti-b2GPI IgG using purified b2GPI protein. Control neutrophils were stimulated with IgG (10 mg/ml) as indicat-
ed for 3 hours. *5P , 0.05. NS5not significant. B, NET release from neutrophils stimulated with the indicated antibodies. Control neutrophils
were treated with purified monoclonal antiphospholipid antibodies (aPL; 10 mg/ml) for 3 hours in the presence or absence of 10% autologous
serum. IS4, aPL, CL1, and CL24 are known to bind b2GPI, while IS1 and IS2 do not. *5P , 0.05; **5P , 0.01; ****5P , 0.0001, versus
control IgG in the presence or absence of serum. C, Fluorescence intensity (corresponding to extracellular DNA) in control neutrophils stimulat-
ed with control IgG, CL1, or 20 nM phorbol myristate acetate (PMA). After 2 hours, PicoGreen was added to the culture, and fluorescence
intensity was measured. Results were normalized to cells permeabilized with 0.1% Triton. ***5P , 0.001. In A–C, bars show the mean6 SEM
of at least 5 independent experiments. D, Representative live cells stained with PicoGreen as described in C. In the sample stimulated with CL1,
expanded cell remnants (encircled areas) are surrounded by a halo of DNA (green). Bars5 25m.
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complexes in vivo (see Supplementary Figure 2, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39247/abstract). Further support-
ing the notion that this predisposition toward NET release
was determined by circulating factors, we were able to
induce NET formation in control neutrophils by incubation
with sera from patients with primary APS (Figure 2C). We
found similar stimulation when treating neutrophils with
sera from patients with secondary APS (Figure 2C). The
clinical characteristics of these patients with secondary
APS (all of whom had SLE) are shown in Supplementary
Table 2, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39247/abstract. In summary, APS neutrophils are predis-
posed to release NETs, an effect that can be replicated by
incubating control neutrophils with the sera of APS patients.
Release of NETs by neutrophils stimulated with
anti-b2GPI IgG. While it is likely that multiple factors
contribute to the ability of APS sera to promote NET
release, we were especially interested in whether aPL may
play a specific role in the process, a concept supported by
the interaction of aPL with other cell types such as mono-
cytes, endothelial cells, and platelets (7,9,10), as well as
the limited studies to date in neutrophils (11,12). Indeed,
we found a positive correlation between anti-b2GPI IgG
and circulating MPO–DNA complexes in APS patients
(see Supplementary Figure 3A, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract). Further, positive testing
for LAC was associated with higher levels of MPO–DNA
(see Supplementary Figure 3B), as was anticardiolipin
IgG (see Supplementary Figure 3C) (although the trend
for the latter was not statistically significant). In contrast,
aPL IgM and IgA did not correlate with circulating MPO–
DNA (see Supplementary Figure 3). Finally, there was a
clear trend for higher levels of circulating MPO–DNA in
patients who were “triple-positive” for anti-b2GPI, anti-
cardiolipin, and LAC, as compared to patients who were
double- and single-positive (Supplementary Figure 3E);
the difference between triple-positive and single-positive
was statistically significant.
Based on the data described above, we selected
5 patients with anti-b2GPI IgG (all triple-positive) and
5 healthy controls, and isolated their total IgG fractions.
The IgG from the APS patients significantly stimulated
NET release as compared to the healthy controls. This
effect was independent of the presence of serum (see
Supplementary Figure 4 [http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract]) and could be abrogated
by specifically depleting the anti-b2GPI fraction (Figure
3A and Supplementary Figure 5 [http://onlinelibrary.
wiley.com/doi/10.1002/art.39247/abstract]). Further, the
stimulation persisted even when the Fc region of APS
IgG was removed. Specifically, APS F(ab0)2 fragments
showed similar activity in NET formation assays as the
parent APS IgG (see Supplementary Figure 6 [http://
onlinelibrary.wiley.com/doi/10.1002/art.39247/abstract]).
To further test whether this effect could be mediat-
ed by anti-b2GPI IgG, we used several well-characterized
human aPL IgG monoclonal antibodies. Two of the anti-
bodies, IS1 and IS2, are known to bind phospholipids in a
b2GPI-independent manner (32), and 3 antibodies, IS4,
CL1, and CL24, are b2GPI-dependent antibodies (32).
While IS1 and IS2 were associated with minimal stimula-
tion of NET formation, the other 3 antibodies all promoted
significant NET release (Figure 3B). Similar to the total
IgG fraction experiments described above, this effect was
independent of human serum (Figure 3B). To gauge the
potency of this NET release by another technique, we
quantified extracellular DNA with PicoGreen, a relatively
cell-impermeable reagent that specifically fluoresces when
associated with dsDNA. Using this technique, we saw simi-
lar quantities of externalized DNA when neutrophils were
treated with the anti-b2GPI monoclonal antibody CL1, as
compared to the well-recognized and robust NET stimula-
tor PMA (Figure 3C). By microscopy, we confirmed that
intact, unstimulated neutrophils demonstrated little fluo-
rescence with PicoGreen staining (Figure 3D). In summa-
ry, anti-b2GPI antibodies promote NET release, both in
total IgG fractions and as human monoclonal antibodies.
Detection of b2GPI on the neutrophil surface. We
had originally hypothesized that an exogenous source of
b2GPI protein (for example, from human serum) would
be necessary for anti-b2GPI–mediated NET release.
However, with both APS IgG fractions and anti-b2GPI
monoclonal antibodies, this was not the case (Figure 3
and Supplementary Figure 4). We therefore investigat-
ed whether b2GPI protein might be detectable in freshly
isolated control neutrophils, as were used for the stimu-
lation experiments described above. By Western blot-
ting, we were able to detect b2GPI in the purified
neutrophils, at a level that was actually higher than that
detected in total PBMCs (Figure 4A). This was in con-
trast to the endothelial cell and monocyte coreceptor
for aPL/b2GPI, annexin A2 (9,45), which was not
detectable in neutrophils (Figure 4A). We also charac-
terized neutrophil b2GPI by immunofluorescence
microscopy. Punctate b2GPI was detectable on unper-
meabilized neutrophils, with no significant change in
the staining pattern with detergent (0.1% Triton) per-
meabilization (Figure 4B). This was in contrast to the
cytoplasmic granule protein neutrophil elastase, which
was detectable only with permeabilization (Figure 4B).
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To further confirm this finding, we quantified
levels of neutrophil-surface b2GPI by flow cytometry.
Indeed, we were able to detect b2GPI on at least 80% of
circulating neutrophils (Figure 4C), which was higher
than the percentage of b2GPI-positive monocytes, by
both our analysis (Figure 4C) and the work of others
Figure 4. b2-glycoprotein I (b2GPI) on the neutrophil surface. A, Left, Western blot of b2GPI, annexin A2, and b-actin in neutrophils and
peripheral blood mononuclear cells (PBMCs) isolated from healthy controls. Total protein extracts were prepared by detergent lysis. Western
blotting was repeated twice with similar results. Right, Densitometric quantification, expressed in arbitrary units. Bars show the mean6 SEM
(n5 6, including 3 samples for each group that are not shown on the Western blot). ***5P , 0.001. B, Representative images of staining for
b2GPI and neutrophil elastase. Neutrophils were isolated from healthy controls and allowed to adhere to coverslips. Cells were then immediately
fixed with paraformaldehyde, and in some cases permeabilized with detergent (0.1% Triton). Green indicates b2GPI or neutrophil elastase; blue
indicates DNA. Bars5 25m. C, Left, Percentage of b2GPI-positive cells in neutrophils and monocytes. Neutrophils and monocytes were identi-
fied by forward/side scatter, and additionally confirmed to be CD10 positive and CD14 positive, respectively. The percentage of b2GPI-positive
cells was then determined. Bars show the mean6 SEM (n5 6 healthy controls for each group). **5P , 0.01. Right, Representative neutrophil
histograms, demonstrating that the majority of CD10-positive cells were also positive for b2GPI.
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(4). Further, the percentage of b2GPI-positive neutro-
phils was not significantly different in APS patients
as compared to healthy controls (see Supplementary
Figure 7, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39247/
abstract). In summary, b2GPI is present on the surface of
neutrophils, where it can potentially mediate anti-b2GPI
binding.
Dependence of aPL-mediated NET release on
reactive oxygen species (ROS) and TLR-4. ROS are
generated during NET formation, and their blockade has
been shown to prevent many (46), but not all (47,48), forms
of NET release. When the aforementioned aPL mono-
clonal antibodies were tested in an H2O2 production assay,
a similar pattern was seen as for NET formation, with IS1
and IS2 yielding minimal activity, and the other 3 monoclo-
nal antibodies demonstrating robust stimulation (see
Supplementary Figure 8A, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract). A similar result was seen
when control neutrophils were stimulated with the total
IgG fractions described above, with APS IgG stimulating
more H2O2 production than control IgG (Supplementary
Figure 8B). We also investigated whether aPL-mediated
NET release could be prevented by an inhibitor of NADPH
oxidase, and consequently ROS formation. Indeed, treat-
Figure 5. Blocking of antiphospholipid antibody (aPL)–mediated neutrophil extracellular trap (NET) release by inhibition of Toll-like receptor
4 (TLR-4) but not TLR-2. A, NET release, determined by immunofluorescence microscopy, from control neutrophils that were stimulated with
control human IgG, an anti–b2-glycoprotein I monoclonal antibody (CL1), or pooled IgG from 5 patients with antiphospholipid syndrome
(APS) (all 10 mg/ml) for 3 hours. Stimulation with lipopolysaccharide (LPS; 100 ng/ml) and phorbol myristate acetate (PMA; 20 nM) served as
controls. Some samples were pretreated with TAK-242, a TLR-4 inhibitor, at 5 mM or 10 mM, as indicated. B, NET release, determined by
immunofluorescence microscopy, from control neutrophils that were stimulated as indicated (with the concentrations described in A) for 3 hours.
Some samples were pretreated with anti–TLR-4, anti–TLR-2, or isotype, at 10 mM or 25 mM, as indicated. Bars show the mean6 SEM (n5 5
independent experiments per condition). *5P , 0.05; **5P , 0.01; ***5P , 0.001. NS5 not significant.
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ment with DPI potently inhibited NET release (see Supple-
mentary Figure 8C).
In other cell types, such as monocytes and endothe-
lial cells, TLR-4 has been implicated as an important
mediator of aPL stimulation (8,9), while knockout of
TLR-4 has been shown to protect against APS-like disease
in mouse models (49). Further, one study has shown that
aPL activation of neutrophils (albeit without testing NET
release) can be mediated by TLR-4 (12). In this study, we
found that a chemical TLR-4 inhibitor, TAK-242, abrogat-
ed both NET formation (Figure 5A) and H2O2 production
(Supplementary Figure 9 [http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract]) in response to anti-b2GPI
monoclonal antibodies as well as total APS IgG fractions.
A similar inhibition of NET formation was seen with an
anti–TLR-4 blocking antibody, but not with anti–TLR-2
or isotype control (Figure 5B). All antibodies used for
stimulation were free of endotoxin as measured by Limu-
lus amebocyte lysate assay. Further, aPL-mediated stimu-
lation remained effective in the presence of the known
endotoxin inhibitor polymyxin B (see Supplementary Fig-
ure 10, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39247/
abstract). In summary, both ROS formation and TLR-4
engagement are important for aPL-mediated NET
release, in contrast to PMA-stimulated NET formation,
which is TLR-4 independent. Also, TLR-4 signaling here
was not mediated by endotoxin, which is consistent with
Figure 6. Stimulation of thrombin generation by purified antiphospholipid antibodies (aPL), as well as plasma from patients with antiphospholi-
pid syndrome (APS), in a neutrophil- and DNA-dependent manner. A, Representative thrombin (IIa) generation plot demonstrating enhanced
generation when neutrophils are exposed to platelet-poor plasma (from a healthy control) supplemented with aPL CL1 (10 mg/ml). The effect is
not seen with plasma alone or plasma supplemented with control IgG. The effect is disrupted by DNase treatment. B, Representative data dem-
onstrating that control plasma supplemented with anti–b2-glycoprotein I (anti-b2GPI) monoclonal antibodies promotes neutrophil-mediated
thrombin generation. Delta values were calculated relative to the baseline condition (in this case, plasma supplemented with IgG but not neutro-
phils). Data are representative of 3 experiments, all with similar results. C, Thrombin generation in control plasma that was supplemented with
total IgG (10 mg/ml) isolated from 5 healthy controls or 5 patients with primary APS (all anti-b2GPI IgG positive) and then mixed with control
neutrophils alone or neutrophils and DNase. D, Thrombin generation in plasma from healthy controls or patients with primary APS that was mixed
with control neutrophils alone or neutrophils and DNase. In C and D, symbols represent the average of 3 independent assays in individual samples;
horizontal and vertical lines show the mean6 SD. *5P , 0.05; **5P , 0.01. AUC5 area under the curve.
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the work of others studying the interplay between aPL and
TLR-4 in monocytes and endothelial cells (8,9).
Other groups have shown that when neutrophils
are cultured in vitro on poly-L-lysine–coated coverslips
(as was done for many of the stimulation experiments
here), b2 integrin engagement is an important part of
achieving full neutrophil activation and NET release
(50). Indeed, blockade of the b2 integrin Mac-1 with an
anti-CD11b monoclonal antibody prevented NET release
in response to not just aPL, but also PMA (Supplementa-
ry Figure 11 [http://onlinelibrary.wiley.com/doi/10.1002/
art.39247/abstract]). This result emphasizes that parallel
pathways may be necessary to achieve full activation, and
suggests that homotypic and heterotypic cellular interac-
tions should be carefully considered when aPL–neutrophil
interplay begins to be studied in vivo.
Enhancement of thrombin generation by puri-
fied aPL, as well as APS patient plasma, in a neutro-
phil- and DNA-dependent manner. The above findings
are especially important when considered in the context
of the arterial and venous thrombotic events that affect
APS patients. To investigate whether aPL-mediated
NET release has prothrombotic potential, we used a
thrombin generation assay (37). We first found that
thrombin generation is enhanced when control plasma
supplemented with anti-b2GPI monoclonal antibodies is
incubated with control neutrophils (see Figure 6A for
representative data for CL1, and Figure 6B for repre-
sentative numerical data for the 3 anti-b2GPI monoclonal
antibodies known to stimulate NET release). Importantly,
neutrophil-mediated thrombin generation could be at-
tenuated by treatment with recombinant human DNase
(Figures 6A and B), strongly indicating that the effect is
dependent on NET formation and not up-regulation of
surface molecules such as tissue factor. Similarly, the addi-
tion of APS total IgG fractions to control plasma resulted
in enhanced thrombin generation, which could also be
abrogated by DNase treatment (Figure 6C and Supple-
mentary Figure 12A, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39247/abstract).
We were also interested in assessing APS patient
plasma for its effects on neutrophil-dependent thrombin
generation. When APS patients were treated with war-
farin, their plasma uniformly failed to generate throm-
bin in the presence of neutrophils (see Supplementary
Figure 13, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39247/abstract), presumably secondary to the depletion
of thrombin and other vitamin K–dependent factors in
this context. This absence of thrombin generation was
despite NET release being active in these samples
(data not shown). We were able to identify 8 APS plasma
samples that had been isolated from patients who were
not being treated with either warfarin or a heparin-based
anticoagulant. Four of these patients had anti-b2GPI IgG,
while 7 had anticardiolipin IgG. Similar to the aPL-
supplemented control plasma samples (Figures 6A–C),
APS patient plasma was a significant trigger of NET-
mediated thrombin generation (Figure 6D and Supple-
mentary Figure 12B), an effect that could again be abro-
gated by DNase treatment. Importantly, DNase treatment
in the absence of neutrophils had no effect on baseline
thrombin generation (data not shown). In summary, aPL
stimulate neutrophils to release NETs, which then pro-
mote thrombin generation. In this model, thrombin gener-
ation can be prevented by either DNase treatment or
depletion of clotting factors with warfarin.
Correlation of circulating NETs with a history
of arterial thrombosis. As discussed above, circulating
NET levels correlated with both anti-b2GPI IgG levels
and the presence of a LAC phenotype (see Supplementa-
ry Figure 3, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39247/abstract). We also investigated whether circu-
lating NETs and NET release could be predicted by
clinical variables including history of specific events
(Supplementary Table 3 [http://onlinelibrary.wiley.com/
doi/10.1002/art.39247/abstract]) and medications (Sup-
plementary Table 4 [http://onlinelibrary.wiley.com/doi/
10.1002/art.39247/abstract]). Indeed, we found a posi-
tive correlation between history of arterial thrombosis
and circulating cell-free DNA–NETs (P5 0.04). While
other trends existed (for example, fewer circulating
NETs in patients with a history of pregnancy morbidity),
no other correlation reached statistical significance.
DISCUSSION
We have shown for the first time that neutrophils
from patients with APS are predisposed to exaggerated
NET release. This effect seems to predominantly depend
on circulating aPL, since both purified IgG fractions and
anti-b2GPI monoclonal antibodies can promote NET
release. Somewhat surprisingly, we found that the stimula-
tion was not dependent on the addition of an exogenous
source of b2GPI (either in serum or as a purified protein).
This is likely explained by the presence of b2GPI on the
surface of freshly isolated neutrophils. Whether b2GPI is
produced by neutrophils or simply acquired in circulation
is unknown, although its presence on the neutrophil sur-
face is not explained by up-regulation of phosphatidylser-
ine, since isolated neutrophils were consistently negative
for detectable annexin V binding (data not shown). Simi-
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larly, we did not find the monocyte/endothelial receptor
for b2GPI, annexin A2, on the neutrophil surface.
We found a positive correlation in APS patients
between circulating levels of NETs and both anti-b2GPI
IgG and LAC positivity (as well as triple-positivity for
anti-b2GPI, anticardioipin, and LAC). This was despite all
patient samples having been collected outside of acute
thrombotic episodes. We speculate that NET levels would
increase even further at the time of APS-related events, as
is known to happen in the general population for arterial
disease (25), deep vein thrombosis (17), and microscopic
thrombosis (42). Confirmation of this in APS will require
longitudinal investigation. While our in vitro work strongly
supports the notion of a role of aPL in directly promoting
NET release, the higher levels of circulating NETs may
also be partially explained by a recent study demonstrating
an impaired ability of APS sera to degrade NETs in vitro
(16), replicating a phenotype first described in SLE (38).
That study did not, however, measure circulating NET lev-
els, nor was the interaction between intact neutrophils and
aPL assessed (16).
A compelling and unusual feature of APS is that it
predisposes to both arterial and venous thrombosis; this is
in contrast to most thrombotic risk factors, which promote
one or the other. As mentioned above, NETs themselves
have also been associated with arterial (25–27,51), as well
as venous (17,20), events. Additionally, there is emerging
evidence of an important role of NETs in cancer-
associated thrombosis (43), another disease process associ-
ated with both arterial and venous vascular disease (52).
Whether aPL–neutrophil interplay has a role in APS preg-
nancy morbidity is unknown, although it is interesting to
note that exaggerated NET release has been seen in non-
autoimmune patients with preeclampsia (53). NETs have
also been linked to thrombotic microangiopathy, for exam-
ple in thrombotic thrombocytopenic purpura (42), a pro-
cess that replicates many features of the catastrophic form
of APS. Although this study was not designed or powered
to comprehensively study clinical correlations, we did
interestingly find an association between the history of
arterial events and circulating NETs. This finding awaits
confirmation in larger and independent cohorts.
Mechanistically, aPL-mediated NET release is
dependent on the production of ROS. Such dependence
has been seen in most (46), but not all (47,48), forms of
NET release. This could have implications for the inter-
play between oxidative stress, neutrophils, and aPL,
with oxidative stress having previously been shown to be
a risk factor for modifications of b2GPI that promote
aPL–b2GPI interaction (54). We additionally found that
aPL activation of neutrophils was at least partially
dependent on TLR-4. Numerous studies have shown
TLR-4 signaling to be important for aPL activation of
both monocytes and endothelial cells (8,9), while TLR-4
mutation protects against APS-like disease in animals
(49). Indeed, our demonstration of this pathway in neu-
trophils is complementary to previous work showing
synergy between LPS and aPL in neutrophil activation
(12). As infections are well recognized to up-regulate
neutrophil TLR-4 (55), one can envision a scenario in
which NET release smolders at a low level in patients
between events, before being dramatically activated in
the setting of an infection (two-hit hypothesis).
To fully understand these pathways, NET release
will need to be studied in vivo using experimental models
of APS. For example, aPL have been shown to indirectly
activate neutrophils through the complement cascade and
the well-recognized neutrophil stimulator C5a (14,15). We
believe that in vitro aPL-mediated NET release is indepen-
dent of C5a, as neither total IgG fractions nor anti-b2GPI
monoclonal antibodies were dependent on the presence of
serum (and exogenous complement) for neutrophil activa-
tion. Further, APS patient sera promoted NET release
even when heat-inactivated (data not shown). However,
with the recognition that phagocytes themselves may gen-
erate and activate complement components (56), we can-
not completely rule out some type of auto-amplification
loop here.
We believe these data have implications for the pro-
thrombotic diathesis inherent to APS. Neutrophils stimu-
lated with aPL promote thrombin generation, an effect that
could be attenuated by DNase treatment, but not treatment
with an anti–tissue factor antibody. We also found that
plasma isolated from APS patients treated with warfarin
generated no detectable thrombin, despite still promoting
NET release. Similarly, heparin can dismantle NETs (17),
and prevent NET/histone-mediated platelet activation
(57). We therefore postulate that these traditional APS
treatments function downstream of NET release.
Regarding other therapies, aspirin, which already
has a role as an adjuvant agent in APS when arterial mani-
festations are present, has been shown to prevent NET
release (58). Antimalarial medications also have a role in
both the criteria and noncriteria manifestations of APS (3).
With evidence that antimalarials interact with, and modu-
late cellular responses to, extrinsic DNA (59), one wonders
if their protective role in APS may be partially attributed to
their interaction with NETs. In terms of novel therapeutics,
peptidylarginine deiminase inhibitors, which prevent NET
release, have shown therapeutic benefits in murine SLE
(36), atherosclerosis (27), and inflammatory arthritis (60),
although they have yet to be tested in APS. Further, DNase
has a protective role in animals in both arterial (stroke and
myocardial infarction) (61), and venous models (20).
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Whether exogenous DNase will ever be a practical means
of disrupting circulating NETs is unclear, although Fc
fusion proteins have been described (62).
Overall, this study clearly demonstrates that aPL
can activate neutrophils to release NETs and hints that
these circulating NETs contribute to thrombotic events.
NET release should be further assessed in experimental
models, with an eye toward more targeted approaches
to therapy for APS patients.
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